Can-Fite Biopharma Ltd ADR stock is traded at $1.55, with a volume of 22,233. It is down -6.63% in the last 24 hours and down -20.51% over the past month. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Previous Close:
$1.66
Open:
$1.64
24h Volume:
22,233
Relative Volume:
0.82
Market Cap:
$4.70M
Revenue:
$407.80K
Net Income/Loss:
-$9.90M
P/E Ratio:
-
EPS:
-$12.45
Net Cash Flow:
-$9.00M
1W Performance:
-3.13%
1M Performance:
-20.51%
6M Performance:
-54.28%
1Y Performance:
-79.98%
1-Day Range:
$1.55$1.64
1-Week Range:
$1.55$1.70
52-Week Range:
$1.50$12.30
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Name
Can-Fite Biopharma Ltd ADRSector
HealthcareIndustry
BiotechnologyPhone
972 3 924 1114Address
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva, IsraelMarket Cap
Revenue
Net Income
Cash Flow
EPS